Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay

References

• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. doi:10.1038/nm.1789.
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson S-J, Piskorz AM, Jimenez-Linan M, Bentley D, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. doi:10.1126/scitranslmed.3003726.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–16373. doi:10.1073/pnas.0507904102.
   PubMed Web of Science ®Google Scholar
• Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229–239. 10.1016/j.annonc.2020.11.007
   Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi:10.1038/nature22364.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, Zarate R, Lozano MD, Zubiri L, Perez-Gracia JL, Martín-Algarra S, González A. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297–304. doi:10.1373/clinchem.2014.230235.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7(12):1394–1403. doi:10.1158/2159-8290.CD-17-0716.
   PubMed Web of Science ®Google Scholar
• Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, Fairclough SR, Zill OA, Sikora M, Mokhtari R, et al. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clin Cancer Res. 2018;24(15):3539–3549. doi:10.1158/1078-0432.CCR-17-3831.
   PubMed Web of Science ®Google Scholar
• Strijker M, Soer EC, de Pastena M, Creemers A, Balduzzi A, Beagan JJ, Busch OR, Delden OM, Halfwerk H, Hooft JE, et al. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Int J Cancer. 2020;146(5):1445–1456. doi:10.1002/ijc.32586.
   PubMed Web of Science ®Google Scholar
• Iijima Y, Hirotsu Y, Amemiya K, Ooka Y, Mochizuki H, Oyama T, Nakagomi T, Uchida Y, Kobayashi Y, Tsutsui T, et al. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. Eur J Cancer. 2017;86:349–357. doi:10.1016/j.ejca.2017.09.004.
   PubMed Web of Science ®Google Scholar
• Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018;24(15):3528–3538. doi:10.1158/1078-0432.CCR-17-3837.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JCH, Barrett JC, Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(28):3375–3382. doi:10.1200/JCO.2016.66.7162.
   PubMed Web of Science ®Google Scholar
• Said R, Guibert N, Oxnard GR, Tsimberidou AM. Circulating tumor DNA analysis in the era of precision oncology. Oncotarget. 2020;11(2):188–211. doi:10.18632/oncotarget.27418.
   PubMedGoogle Scholar
• Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020;26(8):1877–1885. doi:10.1158/1078-0432.CCR-19-3467.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz Jr LA. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother Cancer. 2014;2:42. 10.1186/s40425-014-0042-0
   Google Scholar
• Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nat Cancer. 2020;1(2):176–183. doi:10.1038/s43018-019-0011-0.
   PubMedGoogle Scholar
• Giroux Leprieur E, Herbretau G, Dumenil C, Julie C, Giraud V, Labrune S, Dumoulin J, Tisserand J, Emile J-F, Blons H, et al. Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. Oncoimmunology. 2018;7(5):e1424675. doi:10.1080/2162402X.2018.1424675.
   PubMed Web of Science ®Google Scholar
• Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130–1136. doi:10.1093/annonc/mdx026.
   PubMed Web of Science ®Google Scholar
• Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, Liu L, Chen Y, Liang N, Chen J, et al. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl Lung Cancer Res. 2020;9(2):269–279. doi:10.21037/tlcr.2020.03.17.
   PubMed Web of Science ®Google Scholar
• Chin YM, Takahashi Y, Chan HT, Otaki M, Fujishima M, Shibayama T, Miki Y, Ueno T, Nakamura Y, Low S. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021;112(1):454–464
   PubMed Web of Science ®Google Scholar
• Wilson HL, D’Agostino RB Jr., Meegalla N, Petro R, Commander S, Topaloglu U, et al. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma. Oncologist. 2020;26(2):e279-e289. doi:10.1002/onco.13573.       .
   PubMed Web of Science ®Google Scholar
• Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, et al. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020;26(8):1924–1931. doi:10.1158/1078-0432.CCR-19-0306.
   PubMed Web of Science ®Google Scholar
• Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM. et al. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017;109(12):10.1093/jnci/djx118
   PubMedGoogle Scholar
• Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: the UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Mol Cancer Ther. 2019;18(5):1001–1011. doi:10.1158/1535-7163.MCT-17-1038.
   PubMed Web of Science ®Google Scholar
• Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, Landron S, Johnson J, Kiedrowski LA, Nagy RJ. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res. 2019;25(23):7098–7112. doi:10.1158/1078-0432.CCR-19-1704.
   PubMed Web of Science ®Google Scholar
• lWan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–238.
   PubMed Web of Science ®Google Scholar
• Naumann DN, Hazeldine J, Dinsdale RJ, Bishop JR, Midwinter MJ, Harrison P, Hutchings SD, Lord JM. Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: a prospective observational study. PLoS One. 2017;12(12):e0189870. doi:10.1371/journal.pone.0189870.
   PubMed Web of Science ®Google Scholar
• Duvvuri B, Lood C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front Immunol. 2019;10:502. doi:10.3389/fimmu.2019.00502.
   PubMed Web of Science ®Google Scholar
• Li X, Hu R, Luo T, Peng C, Gong L, Hu J, Yang S, Li Q. Serum cell-free DNA and progression of diabetic kidney disease: a prospective study. BMJ Open Diabetes Res Care. 2020;8(1):e001078. doi:10.1136/bmjdrc-2019-001078.
   PubMed Web of Science ®Google Scholar
• Polina IA, Ilatovskaya DV, DeLeon-Pennell KY. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clin Chim Acta. 2020;503:145–150. doi:10.1016/j.cca.2020.01.013.
   PubMed Web of Science ®Google Scholar
• Teo YV, Capri M, Morsiani C, Pizza G, Faria AMC, Franceschi C, Neretti N. Cell-free DNA as a biomarker of aging. Aging Cell. 2019;18(1):e12890. doi:10.1111/acel.12890.
   PubMed Web of Science ®Google Scholar
• Tirumani SH, Shinagare AB, O’Neill AC, Nishino M, Rosenthal MH, Ramaiya NH. Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. Eur Radiol. 2016;26(1):286–295. doi:10.1007/s00330-015-3829-6.
   PubMed Web of Science ®Google Scholar
• Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148–154. doi:10.1007/BF00300234.
   PubMed Web of Science ®Google Scholar
• Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DSB, Kopetz ES. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One. 2015;10(10):e0140712. doi:10.1371/journal.pone.0140712.
   PubMed Web of Science ®Google Scholar
• Zuur AF, Ieno EN, Elphick CS. A protocol for data exploration to avoid common statistical problems. Methods Ecol Evol. 2010;1(1):3–14. doi:10.1111/j.2041-210X.2009.00001.x.
   Web of Science ®Google Scholar
• Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020;10(12):1842–1853. doi:10.1158/2159-8290.CD-20-0047.
   PubMed Web of Science ®Google Scholar
• Bachet JB, Blons H, Hammel P, Hariry IE, Portales F, Mineur L, Metges J-P, Mulot C, Bourreau C, Cain J, et al. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2020;26(19):5208–5216. doi:10.1158/1078-0432.CCR-20-0950.
   PubMed Web of Science ®Google Scholar
• Jiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, Guo Y, Yi X, Yang L, Huang D, et al. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Front Oncol. 2020;10:1220. doi:10.3389/fonc.2020.01220.
   PubMed Web of Science ®Google Scholar
• An Y, Guan Y, Xu Y, Han Y, Wu C, Bao C, Zhou B, Wang H, Zhang M, Liu W, et al. The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma. Am J Transl Res. 2019;11:6462–6474.
   PubMed Web of Science ®Google Scholar
• Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R, et al. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018;24(24):6248–6256. doi:10.1158/1078-0432.CCR-18-1128.
   PubMed Web of Science ®Google Scholar
• Li J, Jiang W, Wei J, Zhang J, Cai L, Luo M, Wang Z, Sun W, Wang S, Wang C, et al. Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors. J Transl Med. 2020;18(1):293. doi:10.1186/s12967-020-02449-y.
   PubMed Web of Science ®Google Scholar
• Velimirovic M, Juric D, Niemierko A, Spring L, Vidula N, Sa W, Medford A, Parikh A, Malvarosa G, Yuen M, et al. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 2020;1246–1262.4. 10.1200/PO.20.00117
   PubMedGoogle Scholar
• Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, Frio TR, Vaucher I, Raynal V, Bernard V, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer. 2015;136(9):2158–2165. doi:10.1002/ijc.29265.
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;68(4):663–671. doi:10.1136/gutjnl-2017-315852.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926–930. doi:10.1126/science.aar3247.
   PubMed Web of Science ®Google Scholar
• Vu P, Khagi Y, Riviere P, Goodman A, Kurzrock R. Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. JCO Precis Oncol. 2020 Mar 24;4:PO.19.00204. doi: 10.1200/PO.19.00204.
   Web of Science ®Google Scholar
• PN D, Tm B, Vj B, Chua W, YF M, Lynch D, Po J, Luk AWS, Caixeiro N, de Souza P, et al. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a prospective study. Lung Cancer. 2019;134:187–193. doi:10.1016/j.lungcan.2019.06.021.
   PubMed Web of Science ®Google Scholar
• Stawski R, Walczak K, Perdas E, Wlodarczyk A, Sarniak A, Kosielski P, Meissner P, Budlewski T, Padula G, Nowak D, et al. Decreased integrity of exercise-induced plasma cell free nuclear DNA – negative association with the increased oxidants production by circulating phagocytes. Sci Rep. 2019;9(1):15970. doi:10.1038/s41598-019-52409-w.
   PubMedGoogle Scholar
• Jing RR, Wang HM, Cui M, Fang MK, Qiu XJ, Wu XH, Qi J, Wang Y-G, Zhang L-R, Zhu J-H, et al. A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening. Clin Biochem. 2011;44(13):1074–1079. doi:10.1016/j.clinbiochem.2011.06.083.
   PubMed Web of Science ®Google Scholar
• Tsai NW, Lin TK, Chen SD, Chang WN, Wang HC, Yang TM, Lin Y-J, Jan C-R, Huang C-R, Liou C-W, et al. The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke. Clin Chim Acta. 2011;412:476–479. doi:10.1016/j.cca.2010.11.036.
   PubMed Web of Science ®Google Scholar
• Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33(7):662–666. doi:10.1002/pd.4119.
   PubMed Web of Science ®Google Scholar
• Scott FP, Menezes M, Palma-Dias R, Nisbet D, Schluter P, Da Silva Costa F, McLennan AC. Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. J Matern Fetal Neonatal Med. 2018;31(14):1865–1872. doi:10.1080/14767058.2017.1330881.
   PubMed Web of Science ®Google Scholar
• Chan N, Smet ME, Sandow R, Da Silva Costa F, McLennan A. Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: a historical cohort study. BJOG. 2018;125:848–855. doi:10.1111/1471-0528.15006.
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586. doi:10.1200/JCO.2012.45.2011.
   PubMed Web of Science ®Google Scholar
• Avanzini S, Kurtz DM, Chabon JJ, Moding EJ, Hori SS, Gambhir SS, et al. A mathematical model of ctDNA shedding predicts tumor detection size. Sci Adv. 2020;6(50):eabc4308. doi: 10.1126/sciadv.abc4308.
   Web of Science ®Google Scholar
• Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313(1–2):139–142. doi:10.1016/S0009-8981(01)00665-9.
   PubMed Web of Science ®Google Scholar
• Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016;48(10):1273–1278. doi:10.1038/ng.3648.
   PubMed Web of Science ®Google Scholar
• Snyder Matthew W, Kircher M, Hill Andrew J, Daza Riza M, Cell-free SJ. DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016;164:57–68. doi:10.1016/j.cell.2015.11.050.
   PubMed Web of Science ®Google Scholar
• Dvorakova M, Karafiat V, Pajer P, Kluzakova E, Jarkovska K, Pekova S, Krutílková L, Dvořák M. DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment. Oncogene. 2013;32(44):5201–5209. doi:10.1038/onc.2012.553.
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo DC, Dominguez C, Garcia-Arranz M, Anker P, Stroun M, Garcia-Verdugo JM, García-Olmo D. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010;70(2):560–567. doi:10.1158/0008-5472.CAN-09-3513.
   PubMed Web of Science ®Google Scholar
• Nishimoto S, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, Kim-Kaneyama J-R, Sato F, Bando M, Yagi S. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv. 2016;2(3):e1501332. doi:10.1126/sciadv.1501332.
   PubMed Web of Science ®Google Scholar
• Lee JH, Menzies AM, Carlino MS, McEvoy AC, Sandhu S, Weppler AM, Diefenbach RJ, Dawson S-J, Kefford RF, Millward MJ, et al. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clin Cancer Res. 2020;26(15):4064–4071. doi:10.1158/1078-0432.CCR-19-3926.
   PubMed Web of Science ®Google Scholar
• Pereira B, Chen CT, Goyal L, Walmsley C, Pinto CJ, Baiev I, Allen R, Henderson L, Saha S, Reyes S, et al. Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nat Commun. 2021;12(1):3199. doi:10.1038/s41467-021-23394-4.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al, Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. 10.1056/NEJMoa1408617
   PubMed Web of Science ®Google Scholar
• Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928–1937. doi:10.1038/s41591-019-0652-7.
   PubMed Web of Science ®Google Scholar
• Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017;35(14):1598–1605. doi:10.1200/JCO.2016.71.6712.
   PubMed Web of Science ®Google Scholar
• Martincorena I. Somatic mutation and clonal expansions in human tissues. Genome Med. 2019;11(1):35. doi:10.1186/s13073-019-0648-4.
   PubMedGoogle Scholar